Target intelligence / Profile preview

Trans-2,3-enoyl-CoA reductase (TECR)

Target
TECR
Molecular classification
Enzyme, Oxidoreductase, Steroid 5-alpha reductase family
01

Overview

Trans-2,3-enoyl-CoA reductase (TECR) is an endoplasmic reticulum-associated enzyme encoded by the TECR gene in humans, belonging to the steroid 5-alpha reductase family. It catalyzes the final (saturation) step in microsomal long- and very long-chain fatty acid (VLCFA) elongation by reducing trans-2,3-enoyl-CoA intermediates to their saturated acyl-CoA forms using NADPH as a cofactor. TECR plays a central role in the production of saturated and monounsaturated VLCFAs, which are major constituents of sphingolipids, and participates in both lipid biosynthesis and degradation pathways, including an essential step in sphingosine degradation via the sphingosine-1-phosphate metabolic pathway. Mutations in TECR are associated with non-syndromic mental retardation, likely through disruption of neural lipid metabolism.

Other names
TECRTERtrans-2-enoyl-CoA reductaseNADPH-dependent trans-2-enoyl-CoA reductaseacyl-CoA:NADP+ trans-2-oxidoreductaseGPSN2SC2MRT14
02

Mechanism of action

Catalyzes reduction of trans-2,3-enoyl-CoA to saturated acyl-CoA in fatty acid elongation; uses NADPH as electron donor; key step in very long-chain fatty acid and sphingolipid synthesis

03

Biological functions

Very long-chain fatty acid synthesisSphingosine degradationFatty acid elongationLipid metabolismSphingolipid metabolism
04

Disease associations

Non-syndromic mental retardationNeurological disordersLipid metabolism diseases
05

Safety considerations

Mutations can cause non-syndromic intellectual disabilitypossible involvement in disorders of lipid metabolism or neurodevelopmental disease

Beyond the preview

Go deeper on Trans-2,3-enoyl-CoA reductase (TECR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trans-2,3-enoyl-CoA reductase (TECR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call